Poxel Appoints Yves Decadt CEO

Poxel>>>, a biopharmaceutical company, announced the appointment of Yves Decadt>>> as its new Chief Executive Officer, effective June 10, 2026. He succeeds Nicolas Trouche>>>, who oversaw the company's restructuring period since August 2025 and the successful implementation of its Continuation Plan, approved by the France — Antibes Commercial Court>>> in January 2026. Yves Decadt>>>'s priorities include accelerating partnership discussions for the commercialization of Imeglimin outside Japan, with a focus on China and Asian markets, and developing PXL065 for hypertrophic cardiomyopathy (HCM) and metabolic dysfunction-associated steatohepatitis (MASH). His extensive international experience in the pharmaceutical industry, including nearly 20 years at Johnson & Johnson>>>, is expected to drive Poxel>>>'s strategic and commercial objectives. The transition is seen as a logical step to strengthen Poxel>>>'s governance and create value for its stakeholders.